A new experimental pill for pancreatic cancer has delivered what researchers are calling a dramatic survival win in a global Phase 3 trial. Patients who received the drug lived a median 13.2 months, compared with 6.7 months for those on standard chemotherapy, roughly cutting the risk of death by about 60%. The topline announcement this week has given fresh energy to patients and clinicians who have spent years facing a disease that rarely budges for new treatments.
What the Trial Found
Revolution Medicines said the RASolute 302 trial met its primary and key secondary endpoints, reporting a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with investigator-choice chemotherapy and a hazard ratio of 0.40 (p < 0.0001). The company described the drug as generally well tolerated and said it intends to submit the data to the U.S. Food and Drug Administration as part of a New Drug Application, seeking accelerated review under the FDA Commissioner’s National Priority Voucher program. Those topline numbers produced immediate responses from industry and patient-advocacy groups, according to Revolution Medicines.
Trial Design and Status
RASolute 302 randomized previously treated patients with metastatic pancreatic ductal adenocarcinoma to receive either 300 mg of daraxonrasib once daily or investigator-choice cytotoxic chemotherapy, and the study enrolled a broad range of RAS variants. The trial is registered as NCT06625320 on ClinicalTrials.gov, and pancreatic tumors are considered heavily RAS-addicted, with over 90% harboring RAS mutations, a fact repeatedly emphasized by patient groups and investigators. Researchers have said the full dataset will be presented to the scientific community at upcoming meetings.
Side Effects and Safety
Earlier clinical materials show skin rash as the most common treatment-related adverse event. A Revolution Medicines poster of Phase 1/2 data reported rash of any grade in roughly 91% of patients and grade ≥3 rash in about 8% of the 160–300 mg population, with dose interruptions and reductions used to manage symptoms. Local WXYZ health columnist Dr. Partha Nandi noted that most rashes were mild but that more dramatic reactions were sometimes controlled with temporary treatment holds or antibiotics. Those safety signals will be weighed alongside the survival benefit when the full data are released, according to WXYZ.
Reaction and Next Steps
The Pancreatic Cancer Action Network called the results “truly remarkable” and urged a rapid review of the data. Industry coverage noted that the readout came at an interim analysis and that such an early positive signal, along with a planned presentation at the American Society of Clinical Oncology annual meeting, will make subgroup and durability data especially important for regulators and clinicians. Revolution Medicines said it will present detailed results at the ASCO meeting and intends to include the data in regulatory filings globally, as reported by BioPharma Dive.
What Patients Should Know
Experts caution that topline results do not immediately change standards of care, and that full, peer-reviewed data and regulatory reviews still need to play out. Dr. Nandi urges anyone with ongoing symptoms such as unexplained weight loss, abdominal pain, or yellowing of the skin or eyes to see a doctor, and notes that important risk factors include smoking, long-term diabetes, obesity, and chronic pancreatitis. Patients interested in access to the new drug should talk with their oncologist about clinical trials and resources offered by patient-advocacy organizations.
